Clinical Trials
Manhattan Hematology Oncology Associates
- AML- FLT3
- Mantle Cell Lymphoma
- Leukemia and Lymphomas
CLL/SLL and MCL - B-Cell Lymphoma
- Colon Cancer CRC
- Myelofibrosis
- CLL/SLL Non-Hodgkin's
Lymphoma
AML-FLT3
Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.
The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
Mantle Cell Lymphoma
Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
Leukemia and Lymphomas CLL/SLL and MCL
Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) or Mantle cell lymphoma (MCL) Oncternal Study
Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies.
This research study will evaluate an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), for treatment of patients with CLL/SLL or MCL.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
B-Cell Lymphoma Beigene Study
Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib
Now enrolling patients for a phase 2 clinical study for the treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, and Marginal Zone Lymphoma with Zanubrutinib (BGB-3111)
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
Colon Cancer CRC Trial
Now Enrolling Patients for an Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
Myelofibrosis Abbvie Study
Now Enrolling Patients for a Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
CLL/SLL Non-Hodgkin's Lymphoma
Now enrolling patients in A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas
CG-806 is a small molecule kinase inhibitor with the potential to treat patients with broad range of B cell malignancies, including those that are sensitive to and those resistant, refractory, or intolerant to standard therapies, as well as a breadth of patients with AML, including those resistant to current FLT3 inhibitors.
CG-806 is the first agent to potentially inhibit all known forms of both FLT3 and BTK enzymes and to inhibit key oncogenic compensatory pathways without inhibiting kinase generally known to induce toxicity.
Purpose of the study:
- To determine the dose of CG-806 given orally every 12 hours that maintains a biologically active plasma concentration over a period of 28 days.
- To establish the recommended Phase 2 dose (RP2D) of CG-806 for future clinical trials in patients with advanced CLL/SLL or NHL.
- To determine the PK profile of CG-806 when administered orally on an every 12 hour schedule.
- To assess the antitumor activity of CG-806 using imaging and biomarker evaluations.
- To determine the ability of CG-806 to alter the expression of pharmacodynamic biomarkers of drug effect.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Phenoia Browne
clinicaltrials@mhony.com
Meet Our Doctors
Alec Goldenberg, M.D.
Dr. Goldenberg, Founding Physician of Manhattan Hematology Oncology Associates (MHOA), graduated Magna Cum Laude from Brandeis University with High Honors in Mathematics, before receiving his MD from The Johns Hopkins University School of Medicine in 1980. He completed his internship and residency at Bellevue-New York University Hospitals, where he was also Chief Resident. Dr. Goldenberg continued his training as a fellow at Memorial Sloan Kettering in New York City before becoming the Director of the Hematology Clinic at the NYU Medical Center. Board certified in Internal Medicine and Medical Oncology, Dr. Goldenberg is currently a Clinical Associate Professor of Medicine at the New York University School of Medicine, and an Attending Physician at New York University Medical Center.

Karen Haglof, M.D.
Dr. Karen Haglof, Associate Physician at Manhattan Hematology Oncology Associates (MHOA), graduated Summa Cum Laude from City University of New York, Hunter College before receiving her MD with Magna Cum Laude distinction from State University of New York. Completing her internship and residency in Internal Medicine at the University of Florida in Gainesville, Florida, Dr. Haglof continued her post-graduate medical training as a Hematology/Oncology Fellow at New York University in New York City. Dr. Haglof continued her strong relationship with NYU and Bellevue Hospitals, where she is currently an Attending Physician and Clinical Instructor in Hematology and Oncology.

